How Do DLBCL Experts Hone Bispecific Antibodies, CAR T-Cell Therapy?

The subject of the panel discussion on diffuse large B-cell lymphoma (DLBCL) care with Tara Graff, DO, MS, of Mission Cancer and Blood, Ruemu Birhiray, MD, of Hematology Oncology of Indiana, Suzanne Fanning, DO, from Prisma Health Cancer Institute, and Joshua Brody, MD, of the Tisch Cancer Institute at Mount Sinai moves to use of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy. The 4 experts extensively describe how they balance these approaches and determine which is appropriate for a patient, amid considerations such as prior debulking, patient response, and clinical trials.